Protagenic Therapeutics, Inc. - Multiplikator Forward P/S PTIX

Cold chain optimization for peptide delivery ensures operational stability, establishing a foundation for Tcap patent protection and FDA compliance for Protagenic Therapeutics (PTIX). The forward P/S ratio trend on GURU.Markets reflects this resilience, where represents the current metric. Completing the picture is the development of innovative antidepressants that restore the brain's natural balance without side effects.

By outsourcing production and clinical trials, Protagenic Therapeutics (PTIX) minimizes capital expenditures, focusing instead on intellectual capital. The expected P/S metric reflects the market valuation of future revenue streams relative to market capitalization, allowing investors to assess the speed at which scientific developments convert into commercial success and to identify signs of asset overvaluation based on this trend.